BioSpace News Archive

Dr. Ioannis Skaribas, a leader in the field of interventional pain management, is proud to announce that he was recently named a Fellow of the American Society of Anesthesiologists

Company to Provide Services to Leading Health Plan’s Members with Bleeding Disorders; Selected based on its Clinical Expertise and Proprietary Data Reporting Capability, SoleMetrics®

The meeting will be held concurrently with the 24th Annual Meeting of the Society for Neuro-Oncology at the JW Marriott Phoenix Desert Ridge Hotel on Friday, November 22, 2019.

Segra would like to extend a special thank you to all the officials in the Township of Langley that have worked with us to make this project possible.”

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company, reported that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data for the combination of TUSC2 immunogene therapy with an anti-PD1 antibody, pembrolizumab, and for the combination of TUSC2 immunogene therapy, pembrolizumab,

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it is accepting applications for its second annual global competitive grants program, Advocacy for Impact

EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced presentation of preclinical data on ET-01, its leading therapeutic program for patients with β-Thalassemia Major, during the 61st American Society of Hematology (ASH) Annual Meeting taking place in Orlando, FL on December 7-10th, 2019.

Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, today announced that Elizabeth Radcliffe has joined as the company’s Vice President of Finance and Strategy.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced the appointment of Brad Smith to its Board of Directors

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Canada has granted priority review status for the New Drug Submission (NDS) for Gliolan® (5-aminolevulinic acid hydrochloride).